Pathologic Outcomes in Men with Low-risk Prostate Cancer Who Are Potential Candidates for Contemporary, Active Surveillance Protocols

Ho Won Kang,1, Joo Yong Lee,1 Jong Kyu Kwon,1 Seong Uk Jeh,1 Hae Do Jung,2 Kang Su Cho,1 Won Sik Ham,1, and Young Deuk Choi1,3

1Department of Urology, Severance Hospital, Urological Science Institute; 2Department of Urology, Gangnam Severance Hospital, Urological Science Institute; 3Robot and Minimal Invasive Surgery Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

INTRODUCTION

Active surveillance (AS) is an emerging treatment strategy for low-risk prostate cancer (PCa) in response to high rates of over-diagnosis using prostate-specific antigen (PSA) levels as a biomarker (1, 2). AS programs are designed to identify patients with clinically indolent tumors and to avoid or delay definitive treatment in these men (3, 4). While AS appears to be a reasonable approach for insignificant tumors, its widespread acceptance remains limited by a lack of consensus in defining appropriate candidates (5). Inclusion criteria for currently used AS guidelines are usually based on the maximum Gleason score, PSA levels and/or PSA density, clinical stage, number of positive biopsy cores, and percentage of single core involvement (6, 7). Currently, various criteria predicting potentially insignificant disease have attempted to strike a balance between maximizing the number of patients who can avoid treatment and minimizing the number of aggressive cases (3, 4, 8, 9). While considerable effort has been devoted to identifying an optimal AS criteria in a clinical practice, adverse pathological features at radical prostatectomy have been reported in 11%-33.5% of potential candidates for AS (10, 11). In addition, most of AS studies do not yet have emphasized the risk of unintended exclusion of actual insignificant PCa. To address these questions, we compared the discriminative performance of contemporary AS criteria to determine whether contemporary AS protocols could sufficiently discriminate clinically significant from indolent tumors in a cohort of low-risk PCa. Specifically, we also assessed the clinical and biopsy characteristics of pathologically insignificant PCa patients who are not eligible for any criteria of published AS protocols.

MATERIALS AND METHODS

Study design

We retrospectively analyzed 312 patients with low-risk PCa treated with radical prostatectomy by a single surgeon at Severance Hospital between January 2007 and December 2013. Low-risk PCa was defined as clinical stage T1c/T2a, PSA levels of 10 ng/mL or less, and a Gleason score of 6 or less on a multi-core bi-
oppsy according to the D’Amico classification. After exclusion of patients with fewer than 10 cores taken at biopsy and who received neo-adjuvant treatment, 205 subjects satisfied the final inclusion criteria. We identified patients’ eligibility for the inclusion criteria using five AS protocols: Johns Hopkins Medical Institution (JHMI) (12), Memorial Sloan-Kettering Cancer Center (MSKCC) (13), Prostate Cancer Research International Active Surveillance (PRIAS) (14), University of California, San Francisco (UCSF) (15), and University of Miami (UM) (16). Adverse findings were Gleason score upgrade (score 7 or greater) and non-organ-confined cancer on surgical pathology. Pathologically insignificant PCa was defined as being organ-confined with a Gleason score less than or equal to 6 (no Gleason pattern 4/5) and a tumor volume less than 0.5 cm³ (8).

**Statistical analysis**

Continuous variables are shown as the median and interquartile range (IQR). The sensitivity, specificity, and accuracy were calculated using standard formulas: sensitivity = TP/TP+FN; specificity = TN/TN+FP; and accuracy = TP+TN/TP+TN+FP+FN, where TP is the number of true positives, TN is the number of true negatives, FP is the number of false positives, and FN is the number of false negatives. Analysis was performed using SPSS 20.0 software (SPSS Inc., Chicago, IL, USA).

**Ethics statement**

The study was carried out in agreement with applicable laws and regulations, good clinical practices, and ethical principles as described in the Declaration of Helsinki. The institutional review board of Severance Hospital approved the present study protocol (Approval number: 4-2014-0619).

**RESULTS**

Table 1 summarizes the baseline characteristics of the 205 low-risk PCa patients included in the analysis. The median prebiopsy PSA and prostate-specific antigen density were 5.4 ng/mL (IQR 4.3-6.9 ng/mL) and 0.16 ng/mL/g (IQR 0.11-0.23 ng/mL/g), respectively. The majority of men had a biopsy Gleason score of 6 and clinical T1c or T2a disease at the time of diagnosis.

After radical prostatectomy, 61 (29.8%) patients had their disease upgraded in the prostatectomy specimen (5 were upgraded to a Gleason score of 6, 50 were upgraded to a Gleason score of 3+4, 4 were upgraded to a Gleason score of 4+3, and 2 were upgraded to a Gleason score of 8) and 26 (12.7%) had non-organ-confined disease (Table 2). The rates of adverse pathology in patients who qualified for each AS protocol are listed in Table 3. A total of 82% of the patients fulfilled the inclusion criteria of at least one protocol, whereas 18% did not meet any criteria of contemporary five AS protocols. The JHMI protocol was the most stringent, with only 34.1% of the patients fulfilling the JHMI criteria, whereas the MSKCC protocol was the most lenient, with...
78.5% of the patients fulfilling the MSKCC criteria. For the PRIAS, UCSF, and UM criteria, 53.2%, 68.8%, and 46.8% of patients fulfilled these criteria, respectively. Non-organ-confined disease was found in 8.6% to 10.6% of patients, and a Gleason score of 7 or greater disease was found in 18.6% to 23.9% of patients according to the five AS protocols.

Overall, 135 patients (65.9%) had pathologically insignificant PCas. The abilities of each AS protocols to predict pathologically insignificant PCa are described in Table 4. The JHMI protocol showed the highest specificity but lowest sensitivity, whereas the MSKCC protocol showed the highest sensitivity but lowest specificity. Among patients who did not meet any criteria of contemporary five AS protocols, 12 (32.4%) patients had pathologically insignificant cancer (Table 5). There were no significant clinical and biopsy characteristics, which can discriminate pathologically significant from insignificant tumors in a cohort of 12 patients who are not eligible for any criteria of contemporary five AS protocols (data not shown). During the median follow-up of 47 (IQR: 25-72) months, only six patients (2.9%) had a biochemical recurrence. There was no case of cancer-specific death.

### Discussion

The present study investigated the pathologic outcomes in men with low-risk PCas who were potential candidates for contemporary AS protocols. Significant adverse pathology was identified in patients deemed eligible for contemporary AS protocols, but also some patients in whom expectant management would be appropriate are not eligible for any criteria of contemporary five AS protocols. Our results suggest the limited value of currently obtained histological criteria to appropriately select candidates for AS.

Currently, many different criteria of AS protocols are in use, ranging from stringent exclusive criteria to less stringent inclusive criteria (6). Given the current status of numerous AS guidelines with no uniformly accepted standard, no current criteria sufficiently discriminate clinically significant from indolent tumors. Several retrospective studies have emphasized the risk of under-diagnosis (17-20). Even with the most stringent selection criteria, it may be difficult to perfectly differentiate between clinically insignificant and life-threatening PCas (10, 21).

In a recent study by Iremashvili et al., five AS protocols were compared with regard to discriminative ability to predict three pathologic end points in a 391 radical prostatectomy cases. In this study, PRIAS and UM have demonstrated the highest ability to identify patients with insignificant prostate cancer (8). Lee et al. also compared the discriminative ability of five AS protocols and concluded that the PRIAS had the best balance between sensi-

### Table 4. The ability of each active surveillance criterion to identify patients with pathologically insignificant prostate cancer

| Criteria | Included patients | Pathologically insignificant prostate cancer | No (%) | Sensitivity | Specificity | Accuracy |
|----------|------------------|--------------------------------------------|--------|-------------|-------------|----------|
| Total cohort | 205 | 135 (65.9) |        |             |             |          |
| Separate criteria |       |               |        |             |             |          |
| JHMI     | 70   | 55 (78.6)     | 40.7   | 78.6        | 53.7        |          |
| MSKCC    | 161  | 119 (73.9)    | 88.1   | 40.0        | 71.7        |          |
| PRIAS    | 109  | 79 (72.5)     | 58.5   | 57.1        | 58.0        |          |
| UCSF     | 141  | 104 (73.8)    | 77.0   | 47.1        | 66.8        |          |
| UM       | 96   | 72 (75.0)     | 53.3   | 65.7        | 57.6        |          |

| Combined criteria |       |               |        |             |             |          |
| All                | 29    | 24 (82.8)     |        |             |             |          |
| Any                | 168   | 123 (73.2)    |        |             |             |          |
| None               | 37    | 12 (32.4)     |        |             |             |          |

JHMI, Johns Hopkins Medical Institution; MSKCC, Memorial Sloan-Kettering Cancer Center; PRIAS, Prostate Cancer Research International: Active Surveillance; UCSF, University of California, San Francisco; UM, University of Miami.

### Table 5. Clinical and biopsy parameters of pathologically insignificant prostate cancer patients who did not meet any criteria of contemporary five AS protocols

| Case number | PSA (ng/mL) | PSAD (ng/mL) | Ratio of positive cores (%) | Ratio of cancer extent (%) | bGS | Clinical T stage | Pathological results |
|-------------|-------------|--------------|-----------------------------|---------------------------|-----|-----------------|---------------------|
| 1           | 3.97        | 0.13         | 35.71 (5/14)                | 80                        | 6.0 | 1c              | 6.00 2c 0.4         |
| 2           | 3.84        | 0.09         | 41.67 (5/12)                | 60                        | 6.0 | 1c              | 6.00 2a 0.2         |
| 3           | 6.20        | 0.21         | 10.00 (1/10)                | 80                        | 6.0 | 2a              | 6.00 2b 0.3         |
| 4           | 6.96        | 0.26         | 16.67 (2/12)                | 70                        | 6.0 | 2a              | 6.00 2b 0.3         |
| 5           | 4.58        | 0.22         | 36.36 (4/11)                | 70                        | 6.0 | 2a              | 6.00 2b 0.3         |
| 6           | 6.06        | 0.20         | 30.00 (3/10)                | 70                        | 6.0 | 1c              | 6.00 2c 0.1         |
| 7           | 6.71        | 0.23         | 41.67 (5/12)                | 60                        | 6.0 | 2a              | 6.00 2b 0.3         |
| 8           | 6.11        | 0.10         | 25.00 (3/12)                | 60                        | 6.0 | 1c              | 6.00 2c 0.1         |
| 9           | 4.30        | 0.26         | 33.33 (4/12)                | 30                        | 6.0 | 1c              | 6.00 2a 0.2         |
| 10          | 9.41        | 0.52         | 50.00 (5/10)                | 5                         | 6.0 | 2a              | 6.00 2b 0.3         |
| 11          | 8.29        | 0.09         | 40.00 (4/10)                | 30                        | 6.0 | 1c              | 6.00 2a 0.3         |
| 12          | 6.74        | 0.15         | 33.33 (4/12)                | 20                        | 6.0 | 1c              | 6.00 2b 0.3         |

PSA, prostate-specific antigen; PSAD, prostate-specific antigen density; bGS, biopsy Gleason score; pGS, pathologic Gleason score.
tivity, specificity and the diagnostic accuracy (11). Our results were similar to those described in previous studies in which significant variations exist in the ability of contemporary AS protocols to predict pathologically insignificant PCa. While numerous investigators described the ability of contemporary AS protocols to predict pathologically insignificant PCa, little is known about the possible exclusion of actual insignificant PCa. Interestingly, 32.4% of patients who did not meet any AS criteria contemporary AS protocols had a pathologically insignificant cancer. These results suggested that none of the currently used clinical or histological criteria have a sufficient sensitivity or specificity for the appropriate selection of candidates for AS (25). Consequently, there is a great need for novel tools such as repeat biopsy, multi-parametric magnetic resonance imaging and various blood markers (PSA isoform/kinetics), or others to blend into selection criteria on active surveillance for low-risk prostate cancer.

Our study has both limitations and strengths. It had a retrospective design, which may have introduced some sampling bias. In addition, our study cohorts were consisted of low-risk PCa according to the D’Amico classification, which could be a confounding factor affecting discriminative performance. Therefore, our results should be viewed as a comprehensive consideration of contemporary AS criteria. On the other hand, our data originated from a single institution and a single surgeon, which minimizing performance variability and bias.

In conclusion, significant adverse pathology was identified in patients deemed eligible for contemporary AS criteria. On the other hand, some patients in whom expectant management was appropriate did not meet any AS criteria. These findings suggest that none of the clinical or histological criteria reported to date is able to sufficiently discriminate aggressive tumors from indolent ones.

DISCLOSURE

The authors have no potential financial conflicts on this subject.

AUTHOR CONTRIBUTION

Conception and design of the study: Kang HW, Jeh SU. Acquisition of data: Kang HW, Kwon JK, Jeh SU. Statistical analysis: Lee JY, Jung HD. First draft of manuscript: Kang HW, Lee JY. Revision and critical review of the manuscript: Cho KS, Ham WS, Choi YD. Manuscript approval: all authors.

ORCID

Ho Won Kang http://orcid.org/0000-0002-8164-4427  
Joo Yong Lee http://orcid.org/0000-0002-3470-1767  
Young Deuk Choi http://orcid.org/0000-0002-8545-5797

REFERENCES

1. Bul M, Zhu X, Rannikko A, Staerman F, Valdagni R, Pickles T, Bangma CH, Roobol MJ. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol 2012; 62: 195-200.

2. Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, Bhatnagar V, Sweeney CJ, Stahle JE, McMahon PM. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 2010; 304: 2573-80.

3. Reese AC, Landis P, Han M, Epstein JL, Carter HB. Expanded criteria to identify men eligible for active surveillance of low-risk prostate cancer at Johns Hopkins: a preliminary analysis. J Urol 2013; 190: 2033-8.

4. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol 2011; 29: 3669-76.

5. Tosoian JJ, John Bull E, Brock BJ, Landis P, Epstein JI, Partin AW, Walsh PC, Carter HB. Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol 2013; 190: 1218-22.

6. Ha YS, Yu J, Salmasi AH, Patel N, Parhpar J, Singer EA, Kim JH, Kwon TG, Kim WJ, Kim YI. Prostate-specific antigen density toward a better cutoff to identify better candidates for active surveillance. Urology 2014; 84: 365-71.

7. Kryvenko ON, Carter HB, Brock BJ, Epstein JI. Biopsy criteria for determining appropriateness for active surveillance in the modern era. Urol 2014; 83: 869-74.

8. Iremashvili V, Pelaez L, Manoharan M, Jorda M, Rosenberg DL, Soloway MS. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols. Eur Urol 2012; 62: 462-8.

9. Dall’Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SI, Klotz LH, Parker C, Soloway MS. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012; 62: 976-83.

10. van den Bergh RC, Ahmed HU, Bangma CH, Cooperberg MR, Villers A, Parker CC. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. Eur Urol 2014; 65: 1023-31.

11. Lee DH, Jung HB, Lee SH, Rha KH, Choi YD, Hong SJ, Yang SC, Chung BH. Comparison of pathological outcomes of active surveillance candidates who underwent radical prostatectomy using contemporary protocols at a high-volume Korean center. Int J Clin Oncol 2012; 14: 1079-85.

12. Tosoian JJ, Brock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011; 29: 2185-90.

13. Adamy A, Yee DS, Matsushita K, Maschino A, Cronin A, Vickers A, Guillonneau B, Scardino PT, Eastham JA. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol 2011; 185: 477-82.

14. Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 2013; 63: 597-603.

15. Dall’Era MA, Konety BR, Cowan JE, Shinohara K, Stoffel E, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011; 29: 2185-90.
for the management of prostate cancer in a contemporary cohort. Cancer 2008; 112: 2664-70.

16. Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 2010; 58: 831-5.

17. Beauval JB, Ploussard G, Soulié M, Pfister C, Van Agt S, Vincendeau S, Larue S, Rigaud J, Gaschignard N, Rouprêt M, et al.; Members of Committee of Cancerology of the French Association of Urology (CCAFU). Pathologic findings in radical prostatectomy specimens from patients eligible for active surveillance with highly selective criteria: a multicenter study. Urology 2012; 80: 656-60.

18. Ploussard G, Salomon L, Xylinas E, Allory Y, Vordos D, Hoznek A, Abou CC, de la Taille A. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria? J Urol 2010; 183: 539-44.

19. Kane CJ, Im R, Amling CL, Presti JC Jr, Aronson WJ, Terris MK, Freedland SJ; SEARCH Database Study Group. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology 2010; 76: 695-700.

20. Han CS, Parihar JS, Kim KY. Active surveillance in men with low-risk prostate cancer: current and future challenges. Am J Clin Exp Urol 2013; 1: 72-82.

21. Berglund RK, Masterson TA, Vora KC, Egggener SE, Eastham JA, Guilonneau BD. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 2008; 180: 1964-7; discussion 7-8.

22. Kates M, Tosoian JJ, Trock BJ, Feng Z, Carter HB, Partin AW. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols. BJU Int 2015; 115: 216-22.

23. Conti SL, Dall’era M, Fradet V, Cowan JE, Simko J, Carroll PR. Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 2009; 181: 1628-33; discussion 33-4.

24. Kim TH, Jeon HG, Choo SH, Jeong BC, Seo SI, Jeon SS, Choi HY, Lee HM. Pathological upgrading and upstaging of patients eligible for active surveillance according to currently used protocols. Int J Urol 2014; 21: 377-81.

25. Seo WI, Kang PM, Kang DI, Yoon JH, Kim W, Chung JI. Cancer of the Prostate Risk Assessment (CAPRA) Preoperative Score Versus Postoperative Score (CAPRA-S); ability to predict cancer progression and decision-making regarding adjuvant therapy after radical prostatectomy. J Korean Med Sci 2014; 29: 1212-6.